Role of omalizumab in refractory chronic spontaneous urticaria: A single referral center experience
Background: Multiple evidence have shown that omalizumab, a subcutaneous (SC) anti-IgE monoclonal antibody, is highly effective for the treatment of chronic spontaneous urticaria (CSU). Objective: The objective is to evaluate the safety and efficacy of omalizumab administered 300 mg SC 1st month fol...
Main Authors: | Gautam Kumar Singh, Manas Chatterjee, Rajesh Verma |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Indian Journal of Drugs in Dermatology |
Subjects: | |
Online Access: | http://www.ijdd.in/article.asp?issn=2455-3972;year=2018;volume=4;issue=1;spage=18;epage=22;aulast=Singh |
Similar Items
-
Omalizumab for management of refractory urticaria: Experience of a tertiary care centre in Eastern India
by: Shekhar Neema, et al.
Published: (2018-01-01) -
Treatment of chronic spontaneous urticaria with a single dose of omalizumab: A study of four cases
by: Radhakrishnan Subramaniyan, et al.
Published: (2016-01-01) -
Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience
by: Joanna Dawicka, et al.
Published: (2016-02-01) -
Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
by: Kiran Godse, et al.
Published: (2016-01-01) -
Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria
by: Eli Magen
Published: (2019-07-01)